论文部分内容阅读
目的:探究氨甲苯酸注射液联合三七胶囊对预防原发性肝癌术中出血的临床观察。方法:收集2013年7月—2015年6月入医院肿瘤科手术切除治疗肝癌患者88例,术前常规行常规检查,对照组患者术前给予氨甲苯酸注射液0.4 g+5%葡萄糖注射液250 m L静脉滴注每次,每日1次;试验组在对照组的基础上给予三七胶囊0.9 g口服,每次,每日2次,连续应用3 d。根据患者情况选择手术方法,手前进行全身麻醉。治疗结束后,对2组患者临床总有效率、手术时间、术中出血量、肺组织量、平均的失血量、出血量≥1000 m L发生率、手术并发症以及1、2、3和5年生存率进行对比分析。结果:研究结果显示,与对照组相比,试验组临床总有效率较高(P<0.05),与对照组相比,试验组术中出血量以及平均的失血量较低(P<0.05),试验组出血量≥1000 m L发生率显著低于对照组(P<0.05)。试验组手术并发症发生率显著低于对照组(P<0.05)。两组治疗后,试验组手术并发症发生率显著低于对照组(P<0.05),试验组1、2、3和5年生存率显著高于对照组(P<0.05)。结论:氨甲苯酸注射液联合三七胶囊能够有效预防原发性肝癌术中出血,降低手术并发症,提高临床疗效以及生存率,适宜临床推广应用。
Objective: To investigate the clinical observation of methotrexate injection combined with Sanchi capsule in the prevention of intraoperative bleeding of primary liver cancer. Methods: Totally 88 patients with hepatocellular carcinoma who underwent surgical resection from July 2013 to June 2015 in our hospital were enrolled. Patients in the control group were given routine preoperative routine tests and patients in the control group received 0.4 g of aminomethyl benzoate injection and 5% glucose injection 250 m L intravenously once a day; the experimental group on the basis of the control group Sanqi capsule 0.9 g orally, twice daily, 3 consecutive days. According to the patient’s condition, select the surgical method, the general anesthesia before hand. After treatment, the total effective rate of the two groups of patients, operation time, intraoperative blood loss, lung tissue volume, average blood loss, bleeding ≥ 1000 m L incidence, complications and 1,2,3 and 5 Year survival rate comparative analysis. Results: The results showed that compared with the control group, the clinical total effective rate was higher in the experimental group (P <0.05), and the blood loss in the experimental group and the mean blood loss were lower than those in the control group (P <0.05) , The incidence of bleeding≥1000 m L in the experimental group was significantly lower than that in the control group (P <0.05). The incidence of surgical complications in the experimental group was significantly lower than that in the control group (P <0.05). After treatment, the incidence of complications in the experimental group was significantly lower than that in the control group (P <0.05). The 1,2,3 and 5-year survival rates in the experimental group were significantly higher than those in the control group (P <0.05). CONCLUSION: Trimetazidine combined with Sanqian Capsule can effectively prevent intraoperative bleeding in patients with primary liver cancer, reduce surgical complications, improve clinical efficacy and survival rate, and is suitable for clinical application.